Cure My Disease

Don't miss your cure!

 Log in / Sign up

New group therapy aims to quiet voices in schizophrenia

NCT ID NCT07266376

Symptom relief Sponsor: Centre Hospitalier Universitaire de la Guadeloupe Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a 15-session group therapy program for people with schizophrenia who still hear voices despite medication. The program combines several proven strategies to help reduce how often the voices occur and how much distress they cause. Researchers will compare the therapy group to a control group to see if it improves symptoms like anxiety and depression. The goal is to offer a non-drug option for managing treatment-resistant auditory hallucinations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
integrative group therapy (behavioral intervention)
What this could lead to
If it works, this program could offer a practical, non-drug way to reduce the frequency and distress of voices for people with schizophrenia who don't respond to medication.
What could go wrong
This is a relatively small, early-stage trial with 116 participants. The therapy is time-intensive (15 weekly sessions) and may not work for everyone. Results may not apply to all people with schizophrenia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 116 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Consenting patients over 18 years of age will be enrolled in the study if they meet all of the following criteria: * Diagnosis: Fulfill DSM-5 criteria for schizophrenia or schizoaffective disorder. * Resistant AVHs: Present treatment-resistant auditory verbal hallucinations (AVHs), defined as the persistence of daily hallucinations without remission despite adequate antipsychotic medication for at least 3 months. * Motivation: Express a request for relief from voices. * Treatment Setting: Are outpatients being treated in psychiatric departments at the Public Mental Health Institution of Guadeloupe or the University Hospital Center of Nîmes. * Severity: Have a score of greater than 9 on the Psychotic Symptom Rating Scale - Auditory Hallucinations subscale (PSYRATS-AH). Exclusion Criteria : Patients will be excluded from the study if they meet any of the following criteria: * Participation in another study: Currently taking part in another clinical trial or within the exclusion period of another study. * Consent refusal: Refuse to sign the written informed consent. * Inability to provide informed consent: Failure or impossibility to provide the patient with sufficient information to allow an informed decision. * Severe substance abuse: Presence of severe substance use disorder. * Acute somatic decompensation: Experiencing an acute medical condition that may compromise participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mental disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hallucinations mental disorder psychiatric disorder schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mental disorder Schizophrenia diagnosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Public Mental Health Institution of Guadeloupe

    Les Abymes, 97139, Guadeloupe

More trials for these conditions

Other studies related to the condition(s) this trial covers.